AI-generated from publicly available materials.Teknova has introduced Build-Tek, an AI-driven custom product configurator that enables rapid creation of complex reagent requests, facilitating a faster transition from preclinical research to clinical manufacturing.
This innovative platform builds on Teknova’s previous custom configurator launched in 2024 and aims to streamline the traditionally intricate custom manufacturing process. By automating product configuration, Build-Tek allows researchers to efficiently design products while ensuring they meet manufacturing standards as projects progress into clinical stages.
Teknova specializes in producing essential reagents for drug discovery and development, including various media and cryopreservation products used in genomics and diagnostics. The introduction of Build-Tek coincides with a notable uptick in Teknova’s business performance, marked by an 18% increase in Q2 revenue to $12.2 million, alongside improvements in gross margin and reduced net losses.
The company has revised its revenue projections for 2026 upwards to between $45 million and $47 million, reflecting confidence in sustained growth as the biotech sector recovers. This strategic move not only enhances Teknova’s operational efficiency but also positions it favorably in a competitive market.